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ABSTRACT
Background Early diagnosis of acute coronary syndrome (ACS) is frequently a challenging task, while immedi-
ate risk stratification remains crucial for the prompt implementation of appropriate therapy in this setting.
Employing markers that increase rapidly after the symptom onset may enhance triage and therapeutic decision-
making in patients suspected for ACS. Myeloperoxidase (MPO) exerting proinflammatory and pro-oxidative
properties is suggested as a reliable early marker for ACS associated with unfavourable clinical outcome. We
assessed the diagnostic efficacy of plasma MPO alone or in combination with cardiac troponin I (cTnI) for
detecting ACS in patients presenting with chest pain initiating within 6 h before the hospital admission.
Material and methods A study group consisted of 253 patients diagnosed with ACS and 47 subjects having
other heart disease or unspecified chest pain. Clinically healthy volunteers (n = 124) served as controls. MPO
concentration was measured in plasma (Abbott Diagnostics, USA), while serum was assayed for cTnI,
creatine-kinase MB, lipids, glucose, creatinine, brain natriuretic peptide type B and C-reactive protein.
Results Both MPO and cTnI values were significantly lower in non-ACS subjects than in patients with ACS. At
97Æ5th percentile as cut-off, the superiority of MPO over cTnI was observed in patients with unstable angina and
non-ACS subjects. Considerably higher MPO concentrations were demonstrated in the troponin-negative ACS
patients on admission who became troponin-positive after 6 h. Combined evaluation of MPO and cTnI
possessed remarkably higher sensitivity than assessment of cTnI alone in all patients with ACS.
Conclusions Myeloperoxidase substantially facilitates the early diagnosis of ACS.
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Introduction
Early diagnosis of acute coronary syndrome (ACS) is frequently
a challenging task, while immediate risk stratification remains
crucial for the prompt implementation of appropriate therapy
in this setting. However, the prolonged release pattern of tropo-
nins, well-established biomarkers of myocardial necrosis, and
limited sensitivity of the routine troponin assay make it difficult
to diagnose ACS at an early stage. Employing markers that
increase rapidly after the symptom onset may enhance triage
and therapeutic decision-making in patients suspected for ACS.
Myeloperoxidase (MPO) possessing proinflammatory and pro-
oxidative properties is suggested as a reliable early marker for
ACS associated with unfavourable clinical outcome [1–6]. The
purpose of this study was to assess the early diagnostic efficacy
of plasma MPO alone or in combination with cardiac troponin I
(cTnI) for detecting ACS in patients presenting with chest pain.
Subjects and methods
Study groups
The study group consisted of 300 patients with suspected ACS
who were admitted to the Department of Cardiology and Inter-
nal Medicine. Of all hospitalized patients, 253 (94 women and
159 men, aged 64 ± 12) met clinical criteria for ACS. Electrocar-
diography examination was performed on admission and
thereafter if clinically indicated. Echocardiography, stress tests
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and cardiac catheterization were performed if needed. Patients
with acute coronary syndrome were subsequently definitely
diagnosed with unstable angina (UA n = 100), non-ST-eleva-
tion myocardial infarction (NSTEMI n = 87) or ST-elevation
myocardial infarction (STEMI n = 66). Forty-seven patients
were diagnosed with other heart disease or unspecified chest
pain. Patients with heart failure, pulmonary embolism, chronic
obstructive pulmonary disease, renal insufficiency and myocar-
dial infarction within 6 weeks preceding the enrolment were
excluded from the trial. Clinically healthy volunteers (40
women and 84 men, aged 49 ± 12 years) with no evidence of
present renal, metabolic or inflammatory disease, heart failure
and recent myocardial infarction served as controls.
Hypertension was diagnosed if systolic blood pressure
exceeded 140 mmHg and ⁄ or diastolic blood pressure was
above 90 mmHg, whereas dyslipidaemia if even one of the
lipid profile components was above ⁄ under the following
values: total cholesterol > 5Æ2 mmol L)1, triglycerides
> 1Æ7 mmol L)1, low density lipoprotein cholesterol
> 3Æ37 mmol L)1, HDL cholesterol < 1Æ3 mmol L)1 for women
and < 1Æ0 mmol L)1 for men according to ESH ⁄ ESC recommen-
dations. Detailed characteristics of study participants were
presented in Table 1.
Methods
Venous blood samples were collected on hospital admission
within 6 h of the chest pain onset. MPO concentration was
measured in K2-EDTA (K2-ethylenediaminetetraacetic acid)
plasma using fully automated chemiluminescent microparticle
immunoassay with Architect ci8200 system; Abbott Diagnos-
tics, Abbott Park, IL, USA. MPO method was validated by the
manufacturer using C28-A2 National Committee for Clinical
Laboratory Standards and EP5-A2 Clinical and Laboratory
Standards Institute (CLSI) protocols. Evaluation of MPO assay
precision was performed in our laboratory with the use of MPO
control material low, medium and high (ref 8L11L, lot
V23785L) according to the CLSI protocol. All within-run and
between-run results were within ±1SD with coefficient of
variation (CV) < 5%.
Otherwise, serum was assayed for cTnI, creatine-kinase MB
(CK-MB) activity, lipid parameters, glucose, creatinine and
brain natriuretic peptide type B (BNP) (Architect ci8200; Abbott
Diagnostics). Additionally, in tested material, we determined
C-reactive protein concentration (hsCRP) using high-sensitivity
method (BNII; Siemens Diagnostics, Warsaw, Poland) and
leucocyte count (WBC) (XE 2100; Sysmex, Kobe, Japan). MPO
was assayed in plasma samples stored frozen at )20 C not
longer than 6 months. cTnI was assayed on admission and after
6 h. Any increase in cTnI above 0Æ032 ng mL)1 (the 99th
percentile for the healthy population measured with 10% CV)
was considered a positive result.
The study was approved by the Ethics Committee at
Collegium Medicum, Nicolaus Copernicus University, Torun,
Poland, and a written informed consent was obtained from all
study participants.
Statistical analysis
Between-group analysis was made with Student’s t-test, Mann–
Whitney U-test, Kruskal–Wallis rank-sum test if appropriate.
Reporting of the study conforms to STARD along with
references to STARD and the broader EQUATOR guidelines.
Clinical sensitivity, specificity, predictive values and area under
the receiver operating characteristic (ROC) curve (AUC) were
quantified. P value £ 0Æ05 was considered significant. Statistical
analysis was performed with Statistica 8.0 and MedCalc 9.6.0.
Results
In the control subjects, median MPO concentration was
143 pmol L)1 with the 95th percentile at 446 pmol L)1, the
97Æ5th at 527 pmol L)1 and the 99th at 609 pmol L)1. Any
elevation of MPO above the 97Æ5th percentile was regarded as
a positive result. Median and 97Æ5th percentile plasma MPO
values among controls were higher in men than in women
(145 vs. 94 pmol L)1 and 527 vs. 380 pmol L)1, respectively),
Table 1 Characteristics of ACS and control groups
(percentages, medians and 25–75 percentiles)
Variables Control group ACS group P
Clinical features
n 124 253
Age (years) 49 ± 12 64 ± 12 –
Women 40 (32%) 94 (37%) –
Men 84 (68%) 159 (63%)
Hypertension 2 (1Æ6%) 187 (74%) –
Diabetes mellitus (0%) 129 (51%) –
Dyslipidaemia 37 (30%) 164 (65%) –
Smoking 64 (52%) 157 (62%) –
ACS family history 35 (28%) 124 (49%) –
Biochemical markers
cTnI ng mL)1 0Æ0 (0Æ0–0Æ0) 0Æ118 (0Æ011–1Æ146) P < 0Æ05
MPO pmol L)1 143 (88–258) 630 (313–1241) P < 0Æ05
hsCRP mg L)1 1Æ02 (0Æ36–2Æ77) 3Æ14 (1Æ2–7Æ9) P < 0Æ05
WBC · 106 5Æ72 (5Æ15–6Æ86) 8Æ33 (6Æ7–10Æ1) P< 0Æ05
BNP (ng mL)1) 21 (10–38Æ4) 97Æ5 (38Æ6–271) P < 0Æ05
ACS, acute coronary syndrome; BNP, brain natriuretic peptide; cTnI, cardiac
troponin I; MPO, myeloperoxidase. Bold values indicate biochemical markers.
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but there were no age-dependent differences (data not
presented).
Concentrations of biomarkers of necrosis (cTnI) and inflam-
mation (hsCRP, MPO, WBC) were significantly higher in
patients with ACS on admission than in control subjects
(Table 1). Median MPO concentrations were considerably
lower in the UA and NSTEMI patients when compared with
the STEMI group (391 and 618 pmol L)1 vs. 1056 pmol L)1,
respectively). In the non-ACS subjects, MPO and cTnI were
significantly lower than in the patients with ACS (MPO
280 pmol L)1; P < 0Æ05 and cTnI 0Æ002 ng mL)1; P < 0Æ05).
ROC analysis was performed for MPO, cTnI and
MPO + cTnI (Fig. 1). At the 97Æ5th percentile for MPO, the
calculated sensitivity and specificity were 55% (48–61; 95% CI)
and 100% (96–100; 95% CI), respectively, with positive and
negative predictive values of 100% (97–100; 95% CI) and 47%
(40–54; 95% CI). For cTnI at 99th percentile cut-off, the sensitiv-
ity and specificity were 66% (60–72; 95% CI) and 100% (96–100;
95% CI), respectively, with positive and negative predictive
values of 100% (98–100; 95% CI) and 54% (47–62; 95% CI). Both
MPO and cTnI alone were characterized by similar, excellent
diagnostic accuracy. The area under the ROC curve for MPO
was 0Æ906 (0Æ870–0Æ934; 95% CI; P = 0Æ0001), whereas for cTnI, it
was 0Æ922 (0Æ889–0Æ948; 95% CI; P = 0Æ0001). ROC analysis for
two-marker strategy MPO + cTnI showed the AUC value of
0Æ931 (0Æ900–0Æ955; 95% CI; P = 0Æ0001).
The evaluation of diagnostic efficacy of plasma MPO in rela-
tion to cTnI was based upon the percentage of positive results
in patients with ACS and non-ACS subjects on admission
(Table 2).
If MPO values at 95th or 97Æ5th percentile were accepted as
cut-off levels, the superiority of MPO over cTnI was observed
only in patients with UA. However, the 97Æ5th percentile cut-off
value allowed for the best discrimination between patients with
ACS and non-ACS cases.
A trend towards higher MPO concentrations in the troponin-
negative patients with ACS on admission who became
troponin-positive after 6 h in comparison with those
consistently troponin-negative was observed (782 pmol L)1 vs.
379 pmol L)1; P = 0Æ09).
Among the troponin-negative patients with UA, 25% of
subjects were positive for MPO. Using the combination of early
assessed MPO and cTnI, we have demonstrated sensitivity of
56% when compared to 31% for cTnI alone in patients with UA
(Fig. 2). Corresponding sensitivity rates in NSTEMI and STEMI
patients for combined MPO + cTnI evaluation of 92% and 100%
were superior to values of 86Æ2% and 91Æ8% obtained on the
basis of cTnI assessment alone.
Discussion
In our study, MPO concentration in plasma, determined shortly
after the onset of chest pain, was significantly elevated in
patients with the final diagnosis of ACS and provided diagnos-
tic information independent from that derived from a well-
established cardiac biomarker: sensitive cTnI. The superiority
Figure 1 ROC analysis of myeloperoxidase (MPO), cardiac
troponin I (cTnI) and MPO + cTnI in the discrimination of
patients with acute coronary syndrome. AUC for cTnI = 0Æ922
(0Æ889–0Æ948; 95% CI; P = 0Æ0001). AUC for MPO = 0Æ906
(0Æ870–0Æ934; 95% CI; P = 0Æ0001). AUC for cTnI + MPO = 0Æ931
(0Æ900–0Æ955; 95% CI; P = 0Æ0001).
Table 2 Diagnostic efficacy of MPO in relation to cTnI in















ACS n = 253 62Æ8 54Æ5 66Æ3
UA n = 100 47Æ0 40Æ0 31Æ0
NSTEMI n = 87 62Æ1 52Æ9 86Æ2
STEMI n = 66 86Æ4 78Æ8 91Æ8
Non-ACS n = 47 17Æ0 0Æ0 12Æ8
ACS, acute coronary syndrome; cTnI, cardiac troponin I; MPO, myeloperoxi-
dase; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina.
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of MPO was observed, above all, in patients with UA, in whom
MPO sensitivity was higher than that of cTnI. Moreover, testing
for MPO in troponin-negative ACS patients added improved
early information in 14% of cases.
Cardiac troponins owing to their superior sensitivity and
specificity for detecting myocardial necrosis are, so far, the best
established biomarkers in cardiology. One of their limitations is
insufficient sensitivity in the early stage of myocardial damage.
Currently, multimarker strategy seems to be more effective for
the diagnosis of ACS and identification of patients suitable for
more aggressive treatment than cardiac troponin alone unless
ultrasensitive assay is used [3,7–9]. The superiority of the two-
marker strategy for early discrimination of patients with ACS
was demonstrated by ROC analysis of MPO + cTnI (AUC 0Æ931
vs. 0Æ906 and 0Æ922 for MPO and cTnI alone).
After early onset of chest pain, both inflammatory and
necrosis markers were highly elevated in our patients with
ACS when compared with the control and non-ACS subjects. It
confirms earlier reports indicating markedly elevated plasma
concentrations of MPO within 2 h of symptom onset in patients
with myocardial infarction [10] or in patients with ACS present-
ing within 3–12 h of their last episode of chest pain [1]. Higher
plasma MPO concentrations in patients with myocardial infarc-
tion compared with patients with UA have also been suggested
in other studies [6,11].
In different reports, the cut-off points for MPO in healthy
population are defined as the 75th, 97Æ5th or 99th percentiles
[6,12,13]. We have accepted the 97Æ5th percentile as the upper
reference value for MPO, which resulted in excellent specificity
and fairly good sensitivity in all patients with ACS and much
better diagnostic efficacy in patients with UA and non-ACS
subjects in comparison with cTnI. The findings of Apple et al.
[13], who used the 99th percentile limit for healthy population,
did not show better diagnostic accuracy of MPO over cTnI in
patients presenting with symptoms suggestive of ACS although
the sensitivity for MPO was higher.
In the recent report, Eggers et al. [6] argued that MPO pro-
vides no clinically relevant information in unselected patients
with chest pain presenting within 8 h. They applied the same
MPO assay as in this study, but their results are not consistent
with ours. In contrast to our data, no significant differences in
median MPO concentrations between patients with UA or myo-
cardial infarction and those with other heart disease or non-car-
diac disease were found. We used the same decision limit, but
MPO concentrations in our non-ACS subjects were found to be
far below the cut-off value. Our study was performed in one
emergency department, whereas the other study was con-
ducted in three different medical centres, which might have
influenced the selection of chest pain patients. Moreover, the
median MPO value and the 97Æ5th percentile in our control
group were much higher than those reported by Eggers et al.
(143 vs.78Æ9 pmol L)1 and 527 vs. 208 pmol L)1, respectively).
This is quite difficult to explain whether we take into consider-
ation the available data of others which, similar to us, have
shown the 95th–99th percentile values for middle-aged healthy
population to vary from 285 to 862 pmol L)1, depending on the
method used [2,12–14].
The impact of collection tube and preanalytical handling on
MPO measurement is a very important aspect as it may lead to
falsely increased results. This has been reported in details by
Shih et al. [15]. They have concluded that for determination of
MPO concentration, the preferred sample type and the most
stable during short storage at room temperature is EDTA
plasma, whereas serum or heparin plasma samples gave consis-
tently higher values because of MPO leakage from leucocytes.
However, this was not the case in our study in which MPO was
measured in EDTA plasma samples frozen within 2 h after
blood collection. Unfortunately, in several studies evaluating
the diagnostic value of MPO in patients with chest pain, serum
was used as an assay material [1,5,14,16] and different ELISA
methods were applied [16–18]. When EDTA plasma was used
for the determination of MPO concentration, a very good
correlation (R2 = 0Æ9204) was shown between ELISA and the
same automated method we have applied [18].
In our study, gender differences in MPO concentrations were
found in the control group which have not been observed by
others [17]. We do not know the reason for this discrepancy;
however, it is worth to note that in the manufacturer’s leaflet,
plasma MPO concentrations at 95th percentile were given as
246Æ6 and 354Æ3 pmol L)1 for women and men, respectively.
Testing for MPO in the troponin-negative ACS patients
added improved early information. In patients who were con-
sistently troponin-negative within 12 h, median MPO concen-
tration was lower than in patients who became cTnI-positive.
The prognostic value of initial MPO measurement in the tropo-
nin-negative patients with chest pain was also reported earlier
[2].
Figure 2 Diagnostic efficacy (%) of two-marker strategy in
patients with acute coronary syndrome on admission.
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In conclusion, MPO, reflecting inflammatory and oxidative
processes distinct from those detected by markers of
necrosis, substantially facilitates the early diagnosis of ACS.
Single plasma MPO measurement obtained within 6 h of the
chest pain onset provides important diagnostic information,
particularly in initially troponin-negative patients. The
diagnostic efficacy of MPO, especially in patients with UA,
may be further enhanced by combined testing for MPO and
cTnI.
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